EQRx Confronts US Drug Development Realities, Shifts Pricing Approach

Company’s $1.5bn To Last Into 2028

 
• By Mandy Jackson
  
Red paper plane is different from the white paper plane. business and leadership concept. airplane change direction.
The drug pricing strategy for EQRx's first two products in the US will differ from elsewhere in the world • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Strategy

More from Business